Early Stage · Biotech
Kurma Biofund IV
The new successor investment fund dedicated to new therapeutic solutions for diseases with high medical need.
158M€
Fund size
2024
1st closing
9
Portfolio companies
7
Team members
Kurma Biofund IV aims to invest in projects and companies in the Life science in Europe and outside Europe, meeting an important medical need.
80% of the Invested Amount will be focused on Portfolio Companies developing therapeutic approaches. Up to 50% of the fund's investments will concentrate on companies established by the Management Company or Argobio.
Size158 million euros
Closing2024 (1st closing)
InterventionCompany creation, venture
SectorBiotechnology Therapeutic
GeographyEurope and outside of Europe
SFDRArticle 8
Investment Team
The Biofund team
Portfolio
Our companies
Latest News
Stay informed
Biotech
January 2026
Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
Read more
Biotech
January 2026
PathoQuest, a Kurma Partners portfolio company, announces a definitive agreement to be acquired by Charles River Laboratories
Read more
Biotech
December 2025
Laigo Bio raises EUR 11.5 million in seed financing
Read more
Biotech
2024
Adcytherix launched with Kurma Partners as founding investor
Read moreBiotech Funds